User: Guest

  

The global market for Osteoporosis Therapeutics is projected to reach US$13.3 billion by 2025, driven by rising awareness over the growing problem of osteoporosis and the ensuing emphasis on early diagnosis and treatment. With the percentage share of people aged 60 plus in the global population mix forecast to reach 21.5% from the current 12.7%, burden of osteoporosis will increase significantly accounting for over 75% of all fractures among the elderly. Although largely preventable, fractures result in long-term injuries, severe pain, long-term disability and high mortality. In the Europe, India, Japan and the United States over 150 million people live with osteoporosis, a number poised to rise significantly in the coming years. Medical emphasis on prevention and early diagnosis will therefore gain prominence providing the cornerstone for growth in the market. As losses in bone mineral density (BMD) is high in the elderly, aging population remains a key growth catalyst, with the risk of osteoporotic hip, vertebral and wrist fracture tripling with age. Economic burden of osteoporotic fractures (OFs) will grow bigger in sync with the aging population growth from 729.3 million people in the age group 65+ in 2020 to over 852.5 million by 2025. The cost of long-term disability from osteoporosis is huge since over 25% of elderly suffering from hip fracture will require permanent nursing home care. Also driving prevalence rates are factors such as rising incidence of vitamin D deficiencies, anorexia nervosa, growing cancer epidemic and increase in the number of patients undergoing chemotherapy and/or using glucocorticoids both of which tend to accelerate the loss of bone mineral density.

The scenario offers a robust outlook for osteoporosis therapeutics. Osteoporosis therapeutics are mainly targeted at reducing the risk of fractures, and are categorized into two main drug categories, named antiresorptive or anabolic. Antiresorptive drugs reduce bone resorption and include mainly bisphosphonates, estrogens, estrogen agonist/ antagonists [EAAs], calcitonin, and denosumab. Anabolic drugs work by increasing bone formation and include teriparatide. Few of the approved drugs for osteoporosis include EVISTA (Selective Estrogen-Receptor Modulator (SERM); DUAVIVE (Estrogen and Selective Estrogen-Receptor Modulator (SERM); FORTEO (Parathyroid Hormone); ACLASTA/ACTONEL (Bisphosphonates); PROLIA (RANK ligand inhibitor); CLIMARA (Hormonal Therapy - Transdermal). Bisphosphonates represent the largest category of drugs for the treatment of osteoporosis and is recommended as the first line of treatment for the prevention of osteoporosis in postmenopausal women, men, and GIO patients. The market also stands to benefit from growing movement in the medical community over the need for further research for safe use of long-term osteoporosis drug therapies for fracture prevention. This will help attract funding support and will speed up the development of new treatments. The United States and Europe represent large markets worldwide with a combined share of 67.2% of the market. China ranks as the fastest growing market with a CAGR of 5.9% over the analysis period supported by attractive reimbursement policies. The national health system and private insurers together reimburse over 75% to 875% of inpatient osteoporosis treatments and 35% to 45% of outpatient care. Traditional Chinese medicine enjoys over is 80% reimbursement.

DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

8177

Interactions with Platform & by Email *

INTERACTIONS

1145

Unique # Participated *

PARTICIPANTS

245

Responses Validated *

VALIDATIONS

46

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
Bisphosphonates.....I-3
  
   Hormone Replacement Therapy/Estrogen Replacement Therapy.....I-4
Estrogens.....I-4
Estrogens/Progesterones.....I-4
Calcitonins.....I-4
Selective Estrogen Receptor Modulators (SERMs).....I-4
Other Therapeutics.....I-4
  
   Generic Incursion Drubs Market Revenues Worldwide.....II-11$100
   Novel Therapies to Recuperate Market Growth.....II-2
Denosumab Bodes Significant Market Opportunities.....II-2
1$100
   Bisphosphonates.....II-3
The leading Therapeutic Market – Only for Now.....II-3
ERT Drugs.....II-3
Ups and Downs in the ERT Market.....II-3
SERMs (Selective Estrogen Receptor Modulators).....II-3
Market Overview.....II-3
1$100
   Calcitonins.....II-4
Market Overview.....II-4
Monoclonal Antibodies (Denosumab).....II-4
Market Overview.....II-4
New Drugs/Drug Classes in Pipeline.....II-4
End-Stage Therapies (Under Development) for Osteoporosis Prevention/Cure.....II-4
1$100
   SERMs.....II-5
Eli Lilly Drops Clinical Study of Arzoxifene for Bone Loss.....II-5
1$100
   Pfizer Intends to Withdraw NDAs for Fablyn.....II-6
Bisphosphonates.....II-6
Zoledronic Acid.....II-6
Pamidronate.....II-6
Calcitonin.....II-6
Emisphere’s Oral Calcitonin Candidate Fails to Clear Clinical Trials.....II-6
1$100
   Parathyroid Hormone (PTH).....II-7
Novartis Terminates Clinical Study of Oral Formulation of PTH1-34.....II-7
Monoclonal Antibodies - Denosumab.....II-7
1$100
   Table 1: Comparison of Major Osteoporosis Drugs in Reducing Risk of Fracture.....II-8
RANK Ligand.....II-8
Combination Therapy.....II-8
1$350
   Others.....II-9
Cathepsin K inhibitors.....II-9
Merck Releases New Data for Odanacatib.....II-9
1$100
   Facts & Figures: The Osteoporosis Primacy.....II-10
Snapshots.....II-10
Table 2: Prevalence of Osteoporosis and Osteopenia in Major Markets including US, Germany, Italy, France, UK, Spain and Japan: 2003-2013 (In Millions) (includes corresponding Graph/Chart).....II-10
Osteoporosis Therapeutics: An Evolutionary Scan.....II-10
1$350
   Currently Available Drugs for Osteoporosis Treatment.....II-11
“A Sketch of the Present Industry Scenario”.....II-11
1$100
   Factors Influencing Demand.....II-12
Altering Competitive Landscape in Osteoporosis Market.....II-12
1$100
   Table 3: Leading Drugs in the Global Osteoporosis Therapeutics Market (2006-2009): Value Sales for Actonel, Fosamax, Evista, Boniva, Forteo and Aclasta/Reclast in US$ Million (includes corresponding Graph/Chart).....II-131$350
   Table 4: Leading Osteoporosis Therapies and its Cost per Day.....II-14
Market Trends and Issues.....II-14
Poor Disease Detection - A Major Market Constraint.....II-14
Reluctance to Undergo HRT to Increase Osteoporosis Burden.....II-14
Patent Expiries to Impact Market Growth.....II-14
1$350
   Limitations Bog Down Current Therapies.....II-15
Growth Opportunities Galore for New Drugs.....II-15
Bisphosphonates to Lose Market Value.....II-15
1$100
   Poor Compliance Mars Use of Bisphosphonates.....II-16
Side Effects of HRT Fuel Natural Alternatives Sales.....II-16
Bone Formation Drugs Augur New Prospects.....II-16
1$100
   A Sneak Into Various Options in Antiresorptives, Anabolic Therapeutics.....II-171$100
   Estrogen Replacement Therapy: Will Dosing Make a Difference?.....II-18
Is Prevention Always Better Than Cure?.....II-18
Peptide-Based Osteoporosis Therapy Gaining Ground.....II-18
Polymorphism- A Potent Diagnostic Marker.....II-18
Bisphosphonates – The Other Side.....II-18
1$100
   Efficacy of Evista under the Scanner.....II-191$100
   The “Silent Thief”.....II-20
An Introduction to Bone Physiology.....II-20
How Osteoporosis Steps In.....II-20
1$100
   Osteoporosis: Major Types.....II-21
Primary Osteoporosis.....II-21
Secondary Osteoporosis.....II-21
1$100
   Osteoporosis - The Aftermath.....II-22
Prevention: The Only Better Way Out.....II-22
Osteoporosis Therapies: A Cursory Glance.....II-22
1$100
   Non-drug Therapy.....II-23
Drug Therapy.....II-23
Major Osteoporosis Therapeutic Classes: A Brief Review.....II-23
Bisphosphonates.....II-23
Classification of Bisphosphonates.....II-23
1$100
   Alendronate II-24 Etidronate.....II-24
Risedronate.....II-24
Calcitonins: A Relatively Safer Therapeutic.....II-24
What It Is.....II-24
What It Does.....II-24
Major Types.....II-24
1$100
   Salmon Calcitonin.....II-25
SERM: A Breakthrough.....II-25
Raloxifene: Most Widely Approved SERM.....II-25
SERMs: The Positive Angle.....II-25
SERMs: The Negative Side.....II-25
1$100
   Hormone Replacement Therapy/Estrogen Replacement Therapy: The Longstanding
  Therapeutic.....II-26
ERT: The Positive Side.....II-26
The Negative Angle to ERT.....II-26
Tereparatide: The First Anabolic Agent.....II-26
1$100
   Composition.....II-27
Forteo: A Leading Brand.....II-27
Major Osteoporosis Therapeutic Classes at a Glance.....II-27
1$100
   Osteoporosis Therapeutics: A Peek into the Major Brands.....II-282$125
   Pfizer Launches Bazedoxifene in Japan.....II-30
Daiichi Files for Approval of Denosumab in Japan.....II-30
Amgen Obtains FDA Approval for Prolia (denosumab) in Treating Post-Menopausal
  Osteoporosis.....II-30
1$100
   Amgen Obtains EC Approval for Marketing Prolia®.....II-31
Teva to Launch Generic Version of Evista.....II-31
Eli Lilly Obtains FDA Approval for Expanded Indication of Forteo®.....II-31
WANBURY Introduces a Calcium Brand, CDENSE, in India.....II-31
1$100
   Yissum Launches New Compound for Osteoporosis Treatment.....II-32
Novartis Bags US Approval for Reclast.....II-32
Wyeth Obtains EC Approval for Conbriza™.....II-32
Ono and Astellas Introduce Bonoteo in Japan.....II-32
1$100
   European Commission Grants Approval to Pfizer for FABLYN® Tablets.....II-331$100
   MDRNA Receives Tentative Approval for New Osteoporosis Drug.....II-34
Novartis Receives EU Approval for Aclasta.....II-34
Sun Pharmaceutical Industries Receives Approval for Fosamax (S).....II-34
Dr Reddy's Obtains Approval for Production and Marketing of Generic Fosamax.....II-34
Aurobindo Pharma Obtains Approval for Introducing Sodium Tablets in the US.....II-34
Procter & Gamble Obtains Approval for Actonel.....II-34
1$100
   Eli Lilly Obtains European Commission Approval for FORSTEO®.....II-35
Ranbaxy Collaborates with Virchow to Introduce Bonista Teriparatide Injection.....II-35
Barr Pharmaceuticals Subsidiary Introduces Generic Osteoporosis Drug.....II-35
Teva Pharmaceutical Industries Obtains Approval for Generic Fosamax® Tablets.....II-35
P&G Receives FDA Approval for New Dosage of Actonel.....II-35
1$100
   Takeda Introduces Benet® for Osteoporosis Treatment.....II-36
Labtec Obtains Approval to Market Hormone Replacement Patch in Europe.....II-36
Wyeth Obtains Conditional Approval for Osteoporosis Drug from FDA.....II-36
Merck’s New Dosage of FOSAMAX PLUS D Gains FDA Approval.....II-36
1$100
   Japanese Pharma Majors Receive Approval for Generic Osteoporosis Drug.....II-37
Roche and GlaxoSmithKline Introduce Bonviva.....II-37
GlaxoSmithKline and Roche Co-Promoted Boniva Receives FDA Approval.....II-37
1$100
   Nycomed’s Preotact Recommended for Approval in Europe.....II-38
Procter & Gamble and Sanofi-Aventis’ Actonel Approved for Male Osteoporosis.....II-38
Upsher-Smith Laboratories Rolls Out Fortical Nasal Spray.....II-38
Teva Receives Tentative FDA Approval for Risedronate Sodium Tablets.....II-38
1$100
   GlaxoSmithKline and Roche Receive Approval for Bonviva in Switzerland.....II-39
Roche’s Once-a-month Bisphosphonate Gets FDA Nod.....II-39
Actonel with Calcium® Obtains FDA Approval.....II-39
FDA Approves Unigene’s Nasal Calcitonin.....II-39
1$100
   Azelon Pharmaceuticals Completes Phase II trails for Comparing Nasal Spray Formulation
  of Teriparatide with Forteo, Administered Subcutaneously.....II-40
GSK & NPS Collaborate for Phase II Clinical Study of Calcilytics.....II-40
Radius Initiates Phase II Trials for BA058.....II-40
1$100
   Novartis and Nordic Initiate Phase III Clinical Trial of Oral Salmon
  Calcitonin.....II-41
Medivir Initiates First Human Trials for MIV-701.....II-41
Osteologix Begins Phase II Trial of NB S101.....II-41
1$100
   Zelos and Nektar Initiates Phase I Clinical Trial of Ostabolin-C™.....II-42
Acceleron Initiates Phase I Clinical Trial of ACE-011.....II-42
Positive Results from Reclast Clinical Trials.....II-42
2$125
   Sanofi Amends Agreement with Warner Chilcott for Actonel®.....II-44
Oramed and Laser Detect Systems Ink Joint Venture Agreement.....II-44
Orchid Chemicals and Pharmaceuticals, and Alvogen Ink Agreement.....II-44
Abbott Takes Over Solvay Pharmaceuticals.....II-44
1$100
   Novartis Obtains Clearance To Continue Clinical Trials on Oral Calcitonin.....II-45
Merck Merges with Schering-Plough.....II-45
Warner Chilcott Acquires Pharmaceuticals Business of P&G.....II-45
Unigene Laboratories Signs Agreement with Tarsa Therapeutics.....II-45
1$100
   Bone Medical Obtains Formal Response from FDA for Capsitonin’s IND.....II-46
US District Court Confirms Validity of Eli Lilly’s Patent for Evista®.....II-46
US District Court Confirms Validity of Unigene's Patent for Fortical®.....II-46
Ajinomoto Announces Japan Rights for Risedronate Hydrate from P&G.....II-46
Amgen and GSK Join Forces to Market Denosumab.....II-46
1$100
   Galapagos-Lily Collaboration Achieves Milestone in Osteoporosis Treatment.....II-47
EffRx and Nycomed Sign Licensing Deal for EX101.....II-47
1$100
   Pfizer Takes Over Wyeth.....II-48
Pfizer Obtains Complete Response Letter from US FDA for Lasofoxifene.....II-48
Wockhardt Signs Agreement with DSM Nutritional for Launch of Bonistein in
  India.....II-48
1$100
   MorphoSys and Galapagos Form Long-Term Development Alliance.....II-49
Daiichi Sankyo Establishes Ireland-Based Subsidiary.....II-49
Merck and Japan Tobacco Sign Global Licensing Agreement for JTT-305.....II-49
Zelos Therapeutics Signs Agreements for Registration Study of ZT-031.....II-49
1$100
   NuVasive Takes Over Osteocal Biologics Business of Osiris Therapeutics.....II-50
Eli Lilly and TransPharma Medical Sign Licensing and Development Agreement.....II-50
Bone Medical Joins Hands with Hyundai Pharm. for Marketing PTH in South Korea.....II-50
1$100
   Eli Lilly to Acquire Osteoporosis Drug Patch from TransPharma Medical.....II-51
Wyeth Obtains Approvable Letter from FDA for Bazedoxifene.....II-51
Daiichi Sankyo Establishes Subsidiary in Turkey.....II-51
Aegis Therapeutics and Zelos Therapeutics Sign Agreement for ZT-031.....II-51
Teijin Pharma Obtains a License from Dong Wha Pharm for DW-1350.....II-51
1$100
   IOF Signs Agreements with Chinese Organizations for Osteoporosis Treatment.....II-52
DAIICHI SANKYO Takes Over EVISTA® from Eli Lilly.....II-52
Daiichi Sankyo Acquires Developing and Marketing Rights for Denosumab in Japan.....II-52
1$100
   Schering-Plough Acquires Organon BioSciences.....II-53
Faes Farma Signs Marketing Agreement with Roche and GlaxoSmithKline.....II-53
Alethia and Emerillon Collaborate on Osteoporosis Therapies.....II-53
Ipsen Enters into Co-marketing Agreement with MSD.....II-53
1$100
   Unigene Enters into Agreement with Novartis.....II-54
Pharming Group Granted Subsidies to Develop Osteoporosis Drugs.....II-54
Procter & Gamble Terminates Nasal Spray Collaboration with Nastech
  Pharmaceutical.....II-54
Pharming Group Acquires DNage.....II-54
1$100
   Amgen Acquires Abgenix.....II-55
P&G Licenses Osteoporosis Nasal Spray Rights from Nastech.....II-55
Eli Lilly to Close Basingstoke Plant.....II-55
Galapagos Acquires Drug Discovery Platform of Discovery Partners.....II-55
1$100
   Duravest Acquires Bio-Magnetic Therapy.....II-56
Galapagos Acquires ProStrakan’s ProSkelia.....II-56
Roche Inks a Marketing Agreement with Elder Pharma.....II-56
1$100
   Chugai and Taisho Sign a Joint Development and Marketing Agreement.....II-57
Theragenex Signs a Licensing Agreement with Zylera.....II-57
Radius Acquires Licensing Agreement for Eisai’s SERMs.....II-57
Alkermes Partners with Eli Lilly to Develop and Market PTH Formulation.....II-57
1$100
   Radius Acquires Exclusive Rights to Karo Bio’s SARMS.....II-58
Unigene Enters into Agreement with Tzamal Bio.....II-58
Galapagos Acquires Inpharmatica.....II-58
Bio-Rad Acquires Provalis Medical Diagnostics Operations.....II-58
1$100
   Daiichi Sankyo to Market Evista in Europe.....II-59
Biocon Acquires Nobex.....II-59
Radius and Ipsen Enters into Licensing Agreement.....II-59
1$100
   Novartis Acquires Hexal AG.....II-60
Nippon Chemiphar Signs Agreement with Velcura Therapeutics.....II-60
Biopotential Capital Acquires Osta Biopharma.....II-60
Dnage Commences DNA Research Programme for Osteoporosis Therapeutics.....II-60
Nastech Initiates Phase I Study of PTH 1-34.....II-60
1$100
   Eli Lilly and Company (US).....II-61
F.Hoffmann-La Roche Ltd (Switzerland).....II-61
Merck & Co., Inc. (US).....II-61
Novartis AG (Switzerland).....II-61
Pfizer, Inc. (US).....II-61
1$100
   Wyeth (US).....II-62
Sanofi SA (France).....II-62
Servier SA (France).....II-62
1$100
   Unigene Laboratories, Inc. (US).....II-63
Warner Chilcott plc (Ireland).....II-63
1$100
   Table 5: World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-641$350
   Table 6: World Historic Review for Osteoporosis Therapeutics by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-651$350
   Table 7: World 15-Year Perspective for Osteoporosis Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....II-661$350
   Table 8: World Recent Past, Current & Future Analysis for Bisphosphonates by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-671$350
   Table 9: World Historic Review for Bisphosphonates by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-681$350
   Table 10: World 15-Year Perspective for Bisphosphonates by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....II-691$350
   Table 11: World Recent Past, Current & Future Analysis for ERT Drugs by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-701$350
   Table 12: World Historic Review for ERT (Estrogen Replacement Therapy) Drugs by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-711$350
   Table 13: World 15-Year Perspective for ERT (Estrogen Replacement Therapy)Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....II-721$350
   Table 14: World Recent Past, Current & Future Analysis for SERMs by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-731$350
   Table 15: World Historic Review for SERMs (Selective Estrogen Receptors Modulators) by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-741$350
   Table 16: World 15-Year Perspective for SERMs (Selective Estrogen Receptors Modulators) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....II-751$350
   Table 17: World Recent Past, Current & Future Analysis for Calcitonins by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-761$350
   Table 18: World Historic Review for Calcitonins by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-771$350
   Table 19: World 15-Year Perspective for Calcitonins by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....II-781$350
   Table 20: World Recent Past, Current & Future Analysis for MAB (Denosumab) by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-791$350
   Table 21: World 15-Year Perspective for MAB (Denosumab) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....II-801$350
   A. Market Analysis.....III-1
Industry Overview.....III-1
Osteoporosis in the US: An Insight.....III-1
Osteoporosis – An Underserved Market?.....III-1
Statistical Review.....III-1
1$75
   Table 22: Osteoporosis Prevalence in Post-Menopause Women (includes corresponding Graph/Chart).....III-21$200
   Table 23: Number of Osteoporosis Patients Undergoing Osteoporosis Therapies (In Thousands) (includes corresponding Graph/Chart).....III-31$200
   Osteoporosis Prescription Market.....III-4
Table 24: US Osteoporosis Prescription Market (2004-2006): Percentage Share of Leading Drugs - Fosamax, Actonel, Evista, Boniva, Forteo and Others (includes corresponding Graph/Chart).....III-4
Competitive Scenario.....III-4
1$200
   Table 25: Leading Players in the US Osteoporosis Market (2004 – A Historic Review) – Market Share by Value Sales for Merck, Eli Lilly, Procter & Gamble/ Sanofi, and Others (includes corresponding Graph/Chart).....III-5
Competitive Review by Segment – A Historic Review.....III-5
Bisphosphonates.....III-5
Table 26: Leading Players in the US Bisphosphonates Market (2004) – Market Share by Value Sales for Merck and Procter & Gamble/ Sanofi (includes corresponding Graph/Chart).....III-5
1$200
   SERMs.....III-6
Calcitonins.....III-6
Patent Expiry of Major Osteoporosis Drugs.....III-6
1$75
   B. Market Analytics.....III-7
Table 27: The US Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, Calcitonins, MAB (Denosumab) and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-7
1$200
   Table 28: The US Historic Review for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, Calcitonins and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-81$200
   Table 29: The US 15-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, Calcitonins, MAB (Denosumab) and Others Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-91$200
   Market Analytics.....III-10
Table 30: Japanese Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB (Denosumab)Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-10
1$200
   Table 31: Japanese Historic Review for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-111$200
   Table 32: Japanese 15-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB (Denosumab) Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-121$200
   A. Market Analysis.....III-13
Forteo: The First Anabolic Agent in Europe.....III-13
European Regulatory Restricts HRT.....III-13
Calcitonin Embraces New Label.....III-13
1$75
   Table 33: European Market for Osteoporosis Therapeutics (2005– A Historic Review): Market Share of Leading Players - Novartis, Merck, Wyeth, Novo Nordisk, Organon, Procter & Gamble, Schering, Solvay and Others (includes corresponding Graph/Chart).....III-141$200
   B. Market Analytics.....III-15
Table 34: European Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Geographic Region – France, Germany, The UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-15
1$200
   Table 35: European Historic Review for Osteoporosis Therapeutics by Geographic Region – France, Germany, The UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-161$200
   Table 36: European 15-Year Perspective for Osteoporosis Therapeutics by Geographic Regions – Percentage Breakdown of Dollar Sales for France, Germany, The UK, Italy, Spain, and Rest of Europe Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-171$200
   Table 37: European Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB (Denosumab) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-181$200
   Table 38: European Historic Review for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-191$200
   Table 39: European 15-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB (Denosumab) Markets for Years2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-201$200
   Market Analytics.....III-21
Table 40: French Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-21
1$200
   Table 41: French Historic Review for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-221$200
   Table 42: French 15-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-231$200
   Market Analytics.....III-24
Table 43: German Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-24
1$200
   Table 44: German Historic Review for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-251$200
   Table 45: German 15-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-261$200
   Market Analytics.....III-27
Table 46: Italian Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-27
1$200
   Table 47: Italian Historic Review for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-281$200
   Table 48: Italian 15-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-291$200
   A. Market Analysis.....III-30
Table 49: Osteoporosis Population in the UK: 2004-2009.....III-30
1$200
   B. Market Analytics.....III-31
Table 50: The UK Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-31
1$200
   Table 51: The UK Historic Review for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-321$200
   Table 52: The UK 15-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-331$200
   Market Analytics.....III-34
Table 53: Spanish Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-34
1$200
   Table 54: Spanish Historic Review for Osteoporosis Therapeutics by Product Group – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-351$200
   Table 55: Spanish 15-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets for Years 2003, 2011& 2017 (includes corresponding Graph/Chart).....III-361$200
   A. Market Analysis.....III-37
Romania.....III-37
B. Market Analytics.....III-37
Table 56: Rest of Europe Recent Past, Current & Future Analysis for Osteoporosis by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-37
1$200
   Table 57: Rest of Europe Historic Review for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-381$200
   Table 58: Rest of Europe 15-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-391$200
   A. Market Analysis.....III-40
Prevalence of Osteoporosis in Various Region - At a Glance.....III-40
Korea.....III-40
Table 59: Korean Osteoporosis Therapeutics Market by Leading Brands (2005 - A Historic Review): Percentage Share Breakdown by Dollar Sales for Fosamax, Atonel, Alend, Maxmarvil, and Others (includes corresponding Graph/Chart).....III-40
China.....III-40
1$200
   B. Market Analytics.....III-41
Table 60: Rest of World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB (Denosumab) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-41
1$200
   Table 61: Rest of World Historic Review for Osteoporosis Therapeutics by Product Groups – Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-421$200
   Table 62: Rest of World 15-Year Perspective for Osteoporosis Therapeutics by Product Group – Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB (Denosumab) Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart).....III-431$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com